ACAD vs BDTX Stock Comparison
ACADIA Pharmaceuticals Inc. vs Black Diamond Therapeutics, Inc.
ACAD leads
ACAD leads by 29 AIQ points, primarily on Quality and Risk Resilience. Wall Street currently favors BDTX on target upside.
Stable: 4 of 5 evidence groups support ACAD, and its current signal state is conflicted.
ACADIA Pharmaceuticals Inc.
Black Diamond Therapeutics, Inc.
The Algovestiq AIQ Score currently favors ACAD over BDTX, 70 versus 41 as of Sep 4, 2026. ACAD's advantage is driven primarily by stronger quality and risk resilience. ACAD also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors BDTX. 4 of 5 covered evidence groups favor ACAD today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. ACAD lead: Stable — the AIQ differential has held near 29 points over 30 sessions.
Compare ACADIA Pharmaceuticals Inc. and Black Diamond Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Compare ACAD and BDTX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality30%92 vs 27ACAD +65
- Risk Resilience15%68 vs 37ACAD +31
- Momentum25%59 vs 59Even
4 of 5 evidence groups favor ACAD. ACAD’s edge is concentrated in quality and risk resilience.
What changed since the last close
Latest scored session 2026-09-03, compared against the prior scored session 2026-09-02.
Largest factor move: Momentum -5
New signals
- BB Lower Band Breach — bullish, volatility, short horizon
Largest factor move: Momentum -2
No new signals fired.
ACAD's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — ACAD and BDTX both carry a full feed there.
The central trade-off
ACAD (ACADIA Pharmaceuticals Inc.): the stronger current systematic profile, led by quality and risk resilience.
BDTX (Black Diamond Therapeutics, Inc.): the counter-case, on analyst expectations — but at materially higher volatility, 50.9% against 36.6%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ACADACAD on the overall AIQ Score, which weights Quality and Value at 30% each.
Growth
ACADACAD on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
ACADACAD on Risk Resilience, by 31 points.
Analyst upside
BDTXBDTX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors ACAD, analyst targets favor BDTX. That disagreement is the most useful thing on this page.
| Measure | ACAD | BDTX | Note |
|---|---|---|---|
| Implied upside to target | +20.3% | +277.4% | BDTX has more room |
| Target dispersion | +102.3% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 9 | 1 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 5 covered evidence groups favor ACAD. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ACAD | 70 vs 41 |
| Fundamentals | ACAD | EPS growth 8% vs -6.3%; TTM ROE 32.4% vs -38.8% |
| Valuation | Not covered | Not covered |
| Technicals | ACAD | Price vs 50-day 3% vs 9.3%; vs 200-day 14% vs -12.7% |
| Risk Resilience | ACAD | Risk Resilience 68 vs 37 |
| Analyst expectations | BDTX | Target upside 20.3% vs 277.4% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ACAD and BDTX and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 29 points. (supports the conclusion holding)
- 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ACAD.
How the comparison changed
120 daily snapshots · Apr 22 – Sep 3ACAD lead: Stable — the AIQ differential has held near 29 points over 30 sessions.
- Today
- ACAD +29
- 70 vs 41
- 7 sessions ago
- ACAD +24
- 69 vs 45
- 30 sessions ago
- ACAD +29
- 74 vs 45
- 90 sessions ago
- ACAD +41
- 74 vs 33
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 1 bearish / 1 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (11.27%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- BB Lower Band Breach — bullish, volatility, short horizon
0 bullish / 2 bearish / 1 neutral
- Death Cross Active — bearish, trend, long horizon (24.01%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.13%)
- MACD Bearish Crossover — bearish, momentum, short horizon
ACAD leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.57%, AIQ -1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.95%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BDTX closes the Quality gap — currently 65 points behind, the largest single contributor to ACAD's edge.
- 2BDTX's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3ACAD's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
- 4A regime shift changes factor weighting — the composite weights Quality and Value at 30% each, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ACAD leads on balance| Metric | ACAD | BDTX |
|---|---|---|
| Revenue growth (YoY) | 14.9% | 0% |
| EPS growth (YoY) | 8% | -6.3% |
| Gross margin | 91.1% | 0% |
| Operating margin | 7.6% | 0% |
| Return on equity (TTM) | 32.4% | -38.8% |
| Debt to equity | 0.06 | 0.18 |
Technicals
ACAD has the stronger structure| Metric | ACAD | BDTX |
|---|---|---|
| RSI (14) | 47.6 | 54.9 |
| ADX (14) | 32.9 | 29 |
| Price vs 50-day | 3% | 9.3% |
| Price vs 200-day | 14% | -12.7% |
| Volatility (1M, annualized) | 36.6% | 50.9% |
Risk
ACAD is the more resilient| Metric | ACAD | BDTX |
|---|---|---|
| Beta | 0.83 | 1.79 |
| Sharpe ratio | 0.3 | 0.01 |
| Sortino ratio | 0.48 | 0.01 |
| Max drawdown | -27.6% | -66.9% |
| Current drawdown | -8.9% | -56.9% |
| Annualized volatility | 38% | 82.7% |
| Value at risk (95%) | -3.5% | -7.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ACAD or BDTX?
On the Algovestiq AIQ Score, ACAD is the stronger of the two as of Sep 4, 2026, scoring 70 against BDTX's 41. The edge comes from quality and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ACAD or BDTX the better buy right now?
ACAD carries the stronger systematic profile as of Sep 4, 2026, and the comparison is rated Stable — 4 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor ACAD over BDTX?
The composite weights Quality at 30%, Value at 30%, Momentum at 25% and Risk Resilience at 15%. ACAD leads Quality by 65 points; ACAD leads Risk Resilience by 31 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ACAD or BDTX?
Analyst price targets imply +20.3% upside for ACAD and +277.4% for BDTX, so the Street currently favors BDTX. That points the opposite way to the AIQ Score, which favors ACAD. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ACAD or BDTX?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ACAD or BDTX?
ACAD on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ACAD or BDTX?
The two are level on Momentum. Momentum carries 25% of the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ACAD or BDTX?
ACAD is the more resilient of the two, so the other name carries the higher downside risk. ACAD on Risk Resilience, by 31 points. The Risk Resilience factor weights 15% of the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ACAD more profitable than BDTX?
ACAD leads on the comparable margin measures — gross margin 91.1% vs 0%; operating margin 7.6% vs 0%; ttm roe 32.4% vs -38.8%.
Is ACAD's lead over BDTX getting stronger or weaker?
ACAD lead: Stable — the AIQ differential has held near 29 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-04-22 and 2026-09-03. The lead has not changed hands in that window.
What would change the ACAD vs BDTX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BDTX closes the Quality gap — currently 65 points behind, the largest single contributor to ACAD's edge; BDTX's Death Cross Active resolves — a bearish trend rule currently active against it; ACAD's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; a regime shift changes factor weighting — the composite weights Quality and Value at 30% each, so a rotation toward either would move the result most.
What do the current signals say about ACAD and BDTX?
ACAD: 4 bullish / 1 bearish / 1 neutral, conflicted. BDTX: 0 bullish / 2 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ACAD is Golden Cross Active (bullish, long horizon). On BDTX it is Death Cross Active (bearish, long horizon).
Compare ACAD and BDTX with others
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality (30%), Value (30%), Momentum (25%) and Risk (15%). Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.